Elevated concentrations of endogenous ouabain in patients with congestive heart failure

Circulation

Volumn 86, Issue 2, 1992, Pages 420-425

  Gottlieb, Stephen S ^a   Rogowski, Amy C ^a   Weinberg, Michelle ^a   Krichten, Catherine M ^a   Hamilton, Bruce P ^a   Hamlyn, John M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Congestive heart failure; Na+,K+ ATPase; Ouabain

Indexed keywords

OUABAIN;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART FUNCTION; HEART INDEX; HEMODYNAMIC PARAMETERS; HOMEOSTASIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASOCONSTRICTION;

DIGOXIN; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEMODYNAMICS; HOMEOSTASIS; HUMAN; IMMUNOASSAY; MALE; MIDDLE AGE; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; SUPPORT, NON-U.S. GOV'T;

EID: 0026637052     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.86.2.420     Document Type: Article

References (35)

1. Thorp RH, Cobbin LB: Cardiac Stimulant Substances. New York, Academic Press, 1967, pp 223-233
2. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci USA 1991;88:6259-6263
3. Bova S, Blaustein MP, Ludens JH, Harris DW, DuCharme DW, Hamlyn JM: Effects of an endogenous ouabainlike compound on heart and aorta. Hypertension 1991;17:944-950
4. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, DuCharme DW: Development of an immunoassay for endogenous digitalis-like factor. Hypertension 1991;17:936-943
5. Hougen TJ, Smith TW: Inhibition of myocardial monovalent cation active transport by subtoxic doses of ouabain in the dog. Circ Res 1978;42:856-863
6. Eisner DA, Lederer WJ: The relationship between sodium pump activity and twitch tension in cardiac Purkinje fibres. J Physiol (Lond) 1980;303:475-494
7. Pamnani MB, Chen S, Bryant HJ, Schooley JF Jr, Eliades DC, Yuan CM, Haddy FJ: Effects of three sodium-potassium adenosine triphosphatase inhibitors. Hypertension 1991;18:316-324
8. Packer M, Medina N, Yushak M: Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catherization in patients with chronic heart failure. Circulation 1985;71:963-971
9. LaFrance ND, Drew HH, Walser M: Radioisotope measurement of glomerular filtration rate in severe chronic renal failure. J Nucl Med 1988;29:1927-1930
10. Mathews WR, DuCharme DW, Hamlyn J, Harris DW, Mandel F, Clark MA, Ludens JH: Mass spectral characterization of an endogenous digitalislike factor from human plasma. Hypertension 1991; 17:930-935
11. Selden R, Margolies MN, Smith TW: Renal and gastrointestinal excretion of ouabain in dog and man. J Pharmacol Exp Ther 1974;188:615-623
12. Gottlieb SS, Kukin ML, Ahern D, Packer M: Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-1539
13. Eichhorn EJ, McGhie AL, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, Deitchman D, Willard JE, Grayburn PA: Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991;67:67-73
14. + pump activity. Hypertension 1982;4:575-580
15. Bealer SL, Haywood JR, Gruber KA, Buckalew VM Jr, Fink GD, Brody MJ, Johnson AK: Preoptic-hypothalamic periventricular lesions reduce natriuresis to volume expansion. Am J Physiol 1983; 244:R51-R57
16. DeMots H, Rahimtoola SH, McAnulty JH, Porter GA: Effects of ouabain on coronary and systemic vascular resistance and myocardial oxygen consumption in patients without heart failure. Am J Cardiol 1978;41:88-93
17. Poston L, Sewell RB, Wilkinson SP, Richardson PJ, Williams R, Clarkson EM, MacGregor GA, de Wardener HE: Evidence of a circulating sodium transport inhibitor in essential hypertension. Br Med J 1981;282:847-849
18. +)ATPase inhibitor associated with essential hypertension. Nature 1982;300: 650-652
19. + pump inhibitory activity in essential hypertension and in normotensive subjects after acute volume expansion. Am J Hypertens 1989;2:524-531
20. +-ATPaSe in patients with essential hypertension. J Hypertens 1988;6:S351-S353
21. Moreth K, Renner D, Schoner W: A quantitative receptor assay for digitalis-like compounds in serum: Demonstration of raised concentrations in essential hypertension and correlation with arterial pressure. Klin Wochenschr 1987;356:36-53
22. +-ATPase inhibitors in hypertension. Hypertension 1991;17:830-836
23. + exchange/hypertension hypothesis. Am J Med 1984;77:45-59
24. Haddy FJ, Overbeck HJ: The role of humoral agents in volume expanded hypertension. Life Sci 1976;19:935-948
25. +,K1-ATPase with high sodium intake in patients with essential hypertension. J Clin Hypertens 1987;3:419-429
26. Hohl AU, Hamilton BP, Hamlyn JM: Dynamics of intracellular calcium, endogenous digitalis and other volume-sensitive hormones during 9-α-fluorohydrocortisone administration to normal man. Abstracts of the Endocrine Society 1990, abstract 835, p 233
27. Schaeffer J, Talartschik J, Koch KM, Rogowski AC, Manunta P, Hamlyn JM: Increased plasma levels of ouabain-like compound (OLC) in dialysis patients: Relationship with interdialytic volume changes? (abstract) J Am Soc Nephrol 1991;2:348
28. Raine AEG, Erne P, Bürgisser E, Muller FB, Bolli P, Burkart F, Bühler FR: Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986;315: 533-537
29. Hamlyn JM, Ludens JH: Non-atrial natriuretic hormones, in Seldin DW, Giebisch G (eds): The Kidney. New York, Raven Press, Publishers (in press)
30. Szent-Gyorgi A: Chemical Physiology of Contraction in Body and Heart Muscle. New York, Academic Press, 1953, pp 86-91
31. Mason DT: Digitalis pharmacology and therapeutics: Recent advances. Ann Intern Med 1974;80:520-530
32. Erdmann E: Influence of cardiac glycosides on their receptor, in Greef K (ed): Cardiac Glycosides, part 1: Experimental pharmacology. New York, Springer-Verlag, 1981, pp 337-380
33. Kim D, Smith TW: Effects of thyroid hormone on sodium pump sites, sodium content, and contractile responses to cardiac glycosides in cultured chick ventricular cells. J Clin Invest 1984;74: 1481-1488
34. Norgaard A, Bjerregaard P, Baandrup U, Kjeldsen K, Reske-Nielson E, Thomsen PEB: The concentration of the Na,K pump in skeletal and heart muscle in congestive heart failure. Int J Cardiol 1990;26:185-190
35. Packer M, Leier CV: Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 1987;75(suppl IV):IV-55-IV-63